{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:16:07Z","timestamp":1790388967498,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ahj.2021.06.013","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T11:08:52Z","timestamp":1625224132000},"page":"38-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations"],"prefix":"10.1016","volume":"241","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-6565","authenticated-orcid":false,"given":"Thomas J.","family":"Povsic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Magnus","family":"Ohman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Pepine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald G.","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd K.","family":"Rosengart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rickey R.","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard C.","family":"Dittrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay H.","family":"Traverse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey A.","family":"Answini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahush A.","family":"Mokadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2021.06.013_bib0001","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.009002","article-title":"Therapeutic approaches for the \"no option\" refractory angina patient","author":"Povsic","year":"2021","journal-title":"Circulation Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2021.06.013_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcin.2019.08.055","article-title":"Refractory Angina: from pathophysiology to new therapeutic nonpharmacological technologies","volume":"13","author":"Gallone","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2021.06.013_bib0003","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.06.013_bib0004","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0140-6736(15)00459-6","article-title":"Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Weisz","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2021.06.013_bib0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.carrev.2019.01.012","article-title":"CD34+ cell therapy for no-option refractory disabling angina: time for fda approval?","volume":"20","author":"Benck","year":"2019","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.ahj.2021.06.013_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2015.10.044","article-title":"Exercise-based cardiac rehabilitation for coronary heart disease: cochrane systematic review and meta-analysis","volume":"67","author":"Anderson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.06.013_bib0007","first-page":"353","article-title":"Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting","volume":"4","author":"Kempf","year":"2011","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.ahj.2021.06.013_bib0008","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001287","article-title":"Predictors of long-term clinical endpoints in patients with refractory angina","volume":"4","author":"Povsic","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2021.06.013_bib0009","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.118.031373","article-title":"Reappraisal of ischemic heart disease","volume":"138","author":"Kaski","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.06.013_bib0010","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s001099900019","article-title":"Molecular and biological properties of vascular endothelial growth factor","volume":"77","author":"Ferrara","year":"1999","journal-title":"J Mol Med"},{"key":"10.1016\/j.ahj.2021.06.013_bib0011","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1161\/01.CIR.101.2.118","article-title":"Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect","volume":"101","author":"Hendel","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.06.013_bib0012","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1161\/01.CIR.0000061911.47710.8A","article-title":"The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis","volume":"107","author":"Henry","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.06.013_bib0013","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/eurheartj\/ehl117","article-title":"Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease","volume":"27","author":"Ripa","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2021.06.013_bib0014","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2004.12.068","article-title":"Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: A randomized double-blind placebo-controlled study: The euroinject One trial","volume":"45","author":"Kastrup","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.06.013_bib0015","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ahj.2010.11.023","article-title":"Intramyocardial plasmid-encoding human vascular endothelial growth factor A165\/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD)","volume":"161","author":"Kukula","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2021.06.013_bib0016","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1161\/01.CIR.0000015982.70785.B7","article-title":"Phase 1\/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia","volume":"105","author":"Losordo","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.06.013_bib0017","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/mt.2009.70","article-title":"Therapy fails to improve perfusion of ischemic myocardium in paitnets with advanced coronary disease: results of the northern trial","volume":"17","author":"Stewart","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.ahj.2021.06.013_bib0018","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ymthe.2005.03.031","article-title":"Alteration of splicing signals in a genomic\/cDNA hybrid VEGF gene to modify the ratio of expressed VEGF isoforms enhances safety of angiogenic gene therapy","volume":"12","author":"Amano","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.ahj.2021.06.013_bib0019","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0022-5223(98)70455-6","article-title":"Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart","volume":"115","author":"Mack","year":"1998","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ahj.2021.06.013_bib0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ymthe.2003.09.014","article-title":"Adenovirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs","volume":"9","author":"Whitlock","year":"2004","journal-title":"Mol Ther"},{"key":"10.1016\/j.ahj.2021.06.013_bib0021","first-page":"643","article-title":"Efficacy and safety of therapeutic angiogenesis from direct myocardial administration of an adenoviral vector expressing vascular endothelial growth factor 165","volume":"115","author":"Zhang","year":"2002","journal-title":"Chin Med J"},{"key":"10.1016\/j.ahj.2021.06.013_bib0022","first-page":"372","article-title":"A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease","volume":"68","author":"Fuchs","year":"2006","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2021.06.013_bib0023","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1161\/01.CIR.0000070540.80780.92","article-title":"Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia","volume":"107","author":"Hedman","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.06.013_bib0024","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/gt.2009.4","article-title":"Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer","volume":"16","author":"Hedman","year":"2009","journal-title":"Gene Ther"},{"key":"10.1016\/j.ahj.2021.06.013_bib0025","doi-asserted-by":"crossref","first-page":"813","DOI":"10.4244\/EIJV6I7A140","article-title":"A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial","volume":"6","author":"Kastrup","year":"2011","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2021.06.013_bib0026","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/hum.2012.137","article-title":"Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease","volume":"24","author":"Rosengart","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ahj.2021.06.013_bib0027","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00000658-199910000-00002","article-title":"Six-month assessment of a phase i trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA","volume":"230","author":"Rosengart","year":"1999","journal-title":"Ann Surg"},{"key":"10.1016\/j.ahj.2021.06.013_bib0028","doi-asserted-by":"crossref","unstructured":"Rosengart TK, Lee Ly, Patel SR, et\u00a0al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100:468-474.","DOI":"10.1161\/01.CIR.100.5.468"},{"key":"10.1016\/j.ahj.2021.06.013_bib0029","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.gt.3302802","article-title":"Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlle trial of AdVEGF121 (AdVEGF121) versus masimum medical treatment","volume":"13","author":"Stewart","year":"2006","journal-title":"Gene Ther"},{"key":"10.1016\/j.ahj.2021.06.013_bib0030","doi-asserted-by":"crossref","first-page":"e12461","DOI":"10.1111\/1755-5922.12461","article-title":"Vascular endothelial growth factor gene transfer therapy for coronary artery disease: A systematic review and meta-analysis","volume":"36","author":"Yuan","year":"2018","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.ahj.2021.06.013_bib0031","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1089\/humc.2013.054","article-title":"Safety of direct cardiac administration of AdVEGF-All6A+, a replication-deficient adenovirus vector cDNA\/genomic hybrid expressing all three major isoforms of human vascular endothelial growth factor, to the ischemic myocardium of rats","volume":"24","author":"Kaminsky","year":"2013","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.ahj.2021.06.013_bib0032","unstructured":"NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, accessed on-line july 19, 2021: https:\/\/osp.od.nih.gov\/wp-content\/uploads\/NIH_Guidelines.pdf."},{"key":"10.1016\/j.ahj.2021.06.013_bib0033","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0003-4975(96)00268-8","article-title":"Direct in vivo gene transfer to canine myocardium using a replication-deficient adenovirus vector","volume":"62","author":"Magovern","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ahj.2021.06.013_bib0034","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.yjmcc.2007.09.012","article-title":"Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction","volume":"44","author":"Perin","year":"2008","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ahj.2021.06.013_bib0035","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1161\/CIRCULATIONAHA.112.000230","article-title":"Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy","volume":"128","author":"Vrtovec","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.06.013_bib0036","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1540-8183.2008.00390.x","article-title":"Transvenous intramyocardial cellular delivery increases retention in comparison to intracoronary delivery in a porcine model of acute myocardial infarction","volume":"21","author":"George","year":"2008","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.ahj.2021.06.013_bib0037","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.06.013_bib0038","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.amjcard.2004.09.025","article-title":"Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris","volume":"95","author":"Rousseau","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2021.06.013_bib0039","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0002-9149(85)90291-7","article-title":"Exercise electrocardiogram and coronary heart disease mortality in the multiple risk factor intervention trial","volume":"55","year":"1985","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2021.06.013_bib0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/oxfordjournals.eurheartj.a059455","article-title":"Increased mortality in men with ST segment depression during 24 h ambulatory long-term ECG recording: results from prospective population study \u2018men born in 1914\u2019, from malmo sweden","volume":"10","author":"Hedbald","year":"1989","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2021.06.013_bib0041","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJMoa013259","article-title":"A controlled trial of arthroscopic surgery for osteoarthritis of the knee","volume":"347","author":"Moseley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.06.013_bib0042","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMoa011858","article-title":"Exercise capacity and mortality among men referred for exercise testing","volume":"346","author":"Myers","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.06.013_bib0043","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/CIRCULATIONAHA.107.734764","article-title":"Exercise capacity and mortality in black and white men","volume":"117","author":"Kokkinos","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.06.013_bib0044","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/CIRCULATIONAHA.110.938852","article-title":"Exercise capacity and mortality in older men","volume":"122","author":"Kokkinos","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.06.013_bib0045","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/eurheartj\/ehx764","article-title":"Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials","volume":"39","author":"Henry","year":"2018","journal-title":"Eur Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321001769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321001769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:58:25Z","timestamp":1762077505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870321001769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":45,"alternative-id":["S0002870321001769"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2021.06.013","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2021.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}